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Abstract The small leucine-rich proteoglycans (SLRPs)
are biologically active components of the extracellular
matrix (ECM), consisting of a protein core with leucine
rich-repeat (LRR) motifs covalently linked to glycosami-
noglycan (GAG) side chains. The diversity in composition
resulting from the various combinations of protein cores
substituted with one or more GAG chains along with their
pericellular localization enables SLRPs to interact with a
host of different cell surface receptors, cytokines, growth
factors, and other ECM components, leading to modulation
of cellular functions. SLRPs are capable of binding to: (i)
different types of collagens, thereby regulating fibril
assembly, organization, and degradation; (ii) Toll-like recep-
tors(TLRs),complementC1q,andtumornecrosisfactor-alpha
(TNFα), regulating innate immunity and inflammation; (iii)
epidermal growth factor receptor (EGF-R), insulin-like growth
factor receptor (IGF-IR), and c-Met, influencing cellular
proliferation, survival, adhesion, migration, tumor growth
and metastasis as well as synthesis of other ECM components;
(iv) low-density lipoprotein receptor-related protein (LRP-1)
and TGF-β, modulating cytokine activity and fibrogenesis;
and (v) growth factors such as bone morphogenic protein
(BMP-4) and Wnt-I-induced secreted protein-1 (WISP-1),
controlling cell proliferation and differentiation. Thus, the
ability of SLRPs,as ECM components, to directly or indirectly
regulate cell-matrix crosstalk, resulting in the modulation of
various biological processes, aptly qualifies these compounds
as matricellular proteins.
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Introduction
Small leucine-rich proteoglycans (SLRPs) are biologically
active components of the extracellular matrix (ECM) and
are structurally characterized by a central protein core made
up of leucine-rich repeats (LRRs) flanked by cysteine-
clusters and substituted with covalently linked glycosami-
noglycan (GAG) side chains (Huxley-Jones et al. 2007,
Iozzo 1998; McEwan et al. 2006; Schaefer and Iozzo
2008). After synthesis, these proteoglycans are secreted into
the pericellular space and abound in the majority of tissues.
They are divided into five distinct classes, based on N-
terminal Cys-rich clusters of the protein core and ear
repeats (C-terminal repeats specific to SLRPs) (McEwan et
al. 2006), chromosomal organization and homologies at the
protein and genomic levels (Table 1; (Schaefer and Iozzo
2008). The GAG chains of SLRPs are sulphated, linear
disaccharide repeating units made from acetylated amino
sugar moieties and uronic acid, forming negatively charged
chondroitin sulphate (CS) or dermatan sulphate (DS)
chains. They are covalently linked to the respective protein
core via serine residues (Gandhi and Mancera 2008;I o z z o
1998). By contrast, the keratan sulphate (KS) GAGs are
composed of repeating disaccharide units containing galac-
tose (-4N-acetyl-glucosamine-β1,3-galactose-β1). Decorin,
biglycan (CS/DS class I proteoglycans) and lumican (KS
class II proteoglycan) are the best characterized members of
the SLRP family.
SLRPs consist of two different structural components,
namely a conserved protein core involved in protein/protein
interactions (Hocking et al. 1998; Iozzo 1997; Kresse et al.
1993) and varying numbers and types of GAG chains in a
single molecule. Along with their pericellular localization,
this allows SLRPs to interact with different molecules and
cell-surface receptors, thereby modulating a wide range of
cell-matrix interactions (Brandan et al. 2008; Iozzo 1998;
Perrimon and Bernfield 2001; Roughley 2006; Schaefer
and Iozzo 2008). These functions were mostly elucidated
by the characterization of specific SLRP-deficient mice
(Ameye et al. 2002; Chakravarti et al. 1998; Chen et al.
2002; Corsi et al. 2002; Danielson et al. 1997; Heegaard et
al. 2007; Svensson et al. 1999; Xu et al. 1998; Young et al.
2002) and are briefly summarized in Table 2. SLRPs were
long known to be able to bind to various types of collagens
thereby regulating the kinetics, assembly, and special
organization of fibrils in skin, tendons, and cornea (Iozzo
1999; Kalamajski and Oldberg 2009; Kresse et al. 1997;
Neame et al. 2000; Reinboth et al. 2006; Schonherr et al.
1995b; Svensson et al. 1995; Wiberg et al. 2002; Zhang et
al. 2006). In the clinical setting, protein core fragments
serve as biological markers for various degenerative
cartilage disorders (Melrose et al. 2008).
However, the biological functions of SLRPs extend far
beyond their interactions with collagens. SLRPs interact
with various cytokines, including transforming growth
factor beta (TGF-β), bone morphogenic protein (BMP-4),
Wnt-I-induced secreted protein-I (WISP-1), von Willebrand
factor (VWF), platelet-derived growth factor (PDGF) and
tumor necrosis factor-alpha (TNFα) (Bi et al. 2007; Chen et
al. 2004; Desnoyers et al. 2001; Guidetti et al. 2004; Inkson
et al. 2009; Kolb et al. 2001; Kresse and Schonherr 2001;
Nili et al. 2003; Tufvesson and Westergren-Thorsson 2002),
leading to modulation of their diverse biological functions.
Pharmacologic manipulations of these interactions could
potentially be exploited for the treatment of proliferative,
inflammatory, and fibrotic disorders (Goldoni and Iozzo
2008; Schaefer and Iozzo 2008; Schaefer et al. 2002;
Schaefer et al. 2004). As extracellular compounds SLRPs
Table 1 Classification of SLRPs
1
Class I Class II Class III Class IV Class V
Biglycan Fibromodulin Epiphycan Chondroadherin Podocan
Decorin Lumican Opticin Nyctalopin Podocan like protein-1
Asporin PRELP Osteoglycan Tsukushi
ECM2 Keratocan
ECMX Osteoadherin
1based on several parameters including conservation and homology at the protein and genomic level, the presence of characteristic N-terminal
Cys-rich clusters with defined spacing, and chromosomal organization (Schaefer and Iozzo 2008)
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receptors (TLRs) (Schaefer et al. 2005), insulin-like growth
factor receptor (IGF-IR) (Schaefer et al. 2007), epidermal
growth factor receptor (EGF-R) (Iozzo et al. 1999), low-
density lipoprotein receptor-related protein (LRP-1) (Brandan
etal.2006), integrin α2β1 (Fiedler et al. 2008; Guidetti et al.
2002), and c-Met (Goldoni et al. 2009), thereby acting as
direct triggers of signal transduction. These interactions
result in modulation of cellular growth, proliferation,
differentiation, survival, adhesion and migration under
developmental, physiological and pathological conditions
(Brandan et al. 2008; Schaefer and Iozzo 2008; Zoeller et al.
2009). For further details regarding the interaction of SLRPs
with cell membrane receptors we refer to more extensive
reviews (Brandan et al. 2008;G o l d o n ia n dI o z z o2008;
Schaefer and Iozzo 2008; Schaefer and Schaefer 2009).
Thus, SLRPs aptly fit the definition of matricellular
proteins due to their: (i) extracellular location, (ii) modu-
latory effects on synthesis, assembly and degradation of
fibrils without being part of the fibrillar structure itself, and
(iii) direct (receptor-mediated) and indirect (via interaction
with cytokines, growth factors and other ECM components)
regulation of cell-matrix crosstalk, influencing a host of
biological processes (e. g. inflammation, fibrosis, tumori-
genesis, angiogenesis, coagulation and wound healing). In
the present review, we focus primarily on the matricellular
functions of decorin, biglycan (class I proteoglycans), and
lumican (class II proteoglycan), which are briefly summa-
rized in Table 3.
SLRPs as modulators of fibrillogenesis, fibrillar
organization and degradation
By their ability to bind to different types of collagens and
elastic fibril components, SLRPs impact on extracellular
matrix organization, modulating the structural and functional
environmentofcells.TheinteractionofSLRPswithcollagens
has been shown to enhance fibril stability (Keene et al. 2000;
Neame et al. 2000) and to protect fibrils from proteolytic
cleavage by various collagenases (Geng et al. 2006).
In vivo, the role of decorin in regulating collagen
fibrillogenesis was elucidated by studies using knockout
mice, which exhibit loosely packed collagen fiber networks
with increased fibril diameter, leading to a skin fragility
phenotype (Danielson et al. 1997; Reed and Iozzo 2002).
The functional importance of decorin in regulating collagen
fibrillogenesis was further emphasized by the altered
mechanical function of lung tissue in decorin-deficient
mice (Fust et al. 2005). Decorin is involved in lateral
growth of collagen fibrils and regulates fibril diameter in
vitro (Danielson et al. 1997). It binds to collagen type I, II,
III, IV, VI, and XIV (Bidanset et al. 1992; Ehnis et al. 1997;
Reed and Iozzo 2002) and has been localized to the ‘d’ and
‘e’ bands of tendon collagen in the “gap zone” (Pringle and
Dodd 1990; Weber et al. 1996). Decorin is also involved in
lateral fusion of collagen I fibrils by binding to the C-
terminus via LRR4-6 of the protein core through protein/
protein interactions, which involves more than one binding
domain (Keene et al. 2000; Kresse et al. 1997; Reed and
Iozzo 2002; Schonherr et al. 1995a; Svensson et al. 1995).
The GAG chain of decorin binds tenascin-X and mediates
its interaction with collagen fibrils, thereby contributing to
extracellular matrix integrity (Elefteriou et al. 2001). Further-
more, the GAG chains are involved in the maintenance of
interfibrillar spacing, which also effects fibril diameter (Iozzo
1999;R a s p a n t ie ta l .2008; Ruhland et al. 2007).
Biglycan-deficient mice do not suffer from increased
skin fragility, but exhibit larger and irregular fibrils leading
to thin dermis and reduced bone mass (Corsi et al. 2002;
Xu et al. 1998). In vitro, biglycan binds to collagen type I,
II, and III but unlike decorin its interaction with collagen
does not appear to influence fibril diameter or fibrillar
kinetics. However, due to its trivalency biglycan could have
a special organizing function on assembly of the extracel-
lular matrix (Douglas et al. 2006; Schonherr et al. 1995b).
This notion is supported by the binding of biglycan to the
N-terminal ends of the collagen VI tetramers. This leads to
Table 2 Characteristics of SLRP-deficient mice
Gene disrupted Phenotype Reference
Biglycan Reduced bone mass with decreased production of bone marrow stromal cells and
larger irregular collagen fibrils indicating an osteoporosis-like phenotype;
Spontaneous aortic dissection and rupture
(Chen et al. 2002; Heegaard
et al. 2007; Xu et al. 1998)
Decorin Skin fragility phenotype with loosely packed collagen networks resembling
Ehlers-Danlos syndrome; Intestinal tumor formation
(Bi et al. 2008; Corsi et al. 2002;
Danielson et al. 1997)
Lumican Skin laxicity and corneal opacity (Chakravarti et al. 1998)
Fibromodulin Abnormal collagen fibrillogenesis in tendons (Svensson et al. 1999)
Biglycan and Decorin Severe osteopenia and increased skin fragility (Young et al. 2002)
Biglycan and
Fibromodulin
Severely altered collagen fibril assembly with ectopic ossification of tendons and
premature arthritis
(Ameye et al. 2002)
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networks, with biglycan being localized at the intra-
network junctions of the collagen VI filaments (Wiberg et
al. 2002). Intact biglycan with GAG chains is required for
complex formation and interaction with the TGF-β-
inducible gene-h3 (beta ig-h3) and collagen VI (Reinboth
et al. 2006). The influence of biglycan on collagen
fibrillogenesis is further demonstrated by the presence of
high amounts of biglycan in keloids (Hunzelmann et al.
1996) and by its localization in the decidualized regions of
the endometrium, regulating fibril thickness in the murine
decidua (San Martin and Zorn 2003). Decorin and biglycan
also regulate collagen fibril assembly coordinately in the
cornea(Zhang et al. 2009) and in tendons (Zhang et al. 2006).
There is some evidence that both SLRPs may also be
involved in elastic fiber biology. Decorin forms complexes
with fibrillin-1, tropoelastin (the soluble precursor of
mature elastin) and microfibril-associated glycoprotein 1
(MAPG-1) (Kielty et al. 1996; Trask et al. 2000). Biglycan
is able to bind to the latter two components (Reinboth et al.
2002). Therefore, both proteoglycans were classified as
microfibril- and elastic fiber-associated molecules (Kielty et
al. 2002). Biglycan regulates elastogenesis as shown by the
ability of its GAG chains to inhibit elastin synthesis and
assembly in the vessel wall (Hwang et al. 2008). Recent
studies have established a molecular link between decorin
and the IGF-IR signaling pathway and the synthesis of
fibrillin-1 in renal fibroblasts. Translational regulation of
fibrillin-1 involves the IGF-IR and the phosphoinositide
3-kinase (PI3K)/Akt pathway, with mammalian target of
rapamycin (mTOR) and p70 S6 kinase as downstream
targets (Fig. 1) (Schaefer et al. 2007). This intriguing
finding indicates that the ECM component decorin is
capable of directly regulating the synthesis of another
matrix constituent (fibrillin-1). This together with the
ability of decorin to regulate the activity of MMPs
(Schonherr et al. 2001), underlines the complexity of
ECM synthesis and turnover under physiological and
pathological conditions.
Lumican-deficient mice suffer from increased skin
fragility and corneal opacities due to abnormal fibril
assembly and altered interfibrillar spacing, indicating a role
in lateral fusion of collagen fibrils (Chakravarti et al. 1998).
Besides maintaining normal fibril architecture of the cornea
by regulating fibril assembly in the posterior stroma,
lumican provides an optimal KS content required for
corneal transparency (Chakravarti et al. 2000). In tendons,
lumican regulates the assembly of fibrils at an early stage of
collagen fibrillogenesis (Ezura et al. 2000). Recently, the
binding site of the lumican protein core to collagen type I
via Asp-213 of LRR7 has been reported (Kalamajski and
Oldberg, 2009).
Fibromodulin, another class II keratan sulphate SLRP
binds to collagen and also regulates fibrillogenesis. Its
deficiency leads to an abnormal tendon phenotype with
impaired collagen fibrils (Svensson et al. 1999; Viola et al.
2007). During tendon development, fibromodulin is involved
in collagen fibrillogenesis, regulating fibril assembly and
Table 3 Matricellular functions modulated by the SLRPs decorin, biglycan and lumican
Biological function modulated Mechanism mediated / involved in modulation
Receptor-binding associated with
signal transduction
EGF-R(D
1
), IGF-IR(D), LRP-1(D), c-Met(D), TLR2(B), TLR4(B) and CD14(L)
Modulation of cytokine bio-activity BMP-4(B), PDGF(D,B), TGF-β(D,B), TNFα(D,B), VWF(D) and WISP-1(D,B)
Fibrillogenesis, fibrillar organization
and degradation
Bind collagens(D,B,L) and elastic fibril components(D,B) regulating fibrillar kinetics(D), assembly(D,L) and
degradation(D,L), thereby modulating the structure, stability and integrity of the ECM.
Adhesion and migration By binding to adhesion(D) and anti-adhesion molecules(D) and also by signaling via IGF-IR(D), integrin
α2β1(D,L), RhoA(D,B), Rac1(D,B), Syk(D) and Erk1/2(L), inhibits or enhances adhesion and migration in
a cell type specific manner.
Cellular proliferation By binding and modulating receptor mediate signaling (EGFR, ErbB4 and VEGF-R2)(D); by
modulating: (i) growth factor bioactivity (TGF-β(D) and PDGF-BB(B)); (ii) cell cycle (influencing
expression of p21(D,L), p27(D,B), cdk2(B) and cyclin D1(L)) and (iii) the myostatin pathway, regulate
cellular growth in a cell and stage-specific manner(D).
Cellular survival Regulate cellular survival by modulating IGF-IR signaling(D), EGFR(D), caspase-3 activity(D,B) and
Fas/FasL-mediated apoptotic pathway(L).
Inflammation and innate immunity Acts as PAMP(B) or presents PAMPs(L) to the receptor thereby triggering or enhancing the inflammatory
response. Also sustains inflammation by regulating chemokine gradient(D,B,L) and complement
activity(D,B).
Fibrosis Potent antifibrotic agent(D), influencing fibrogenesis in different organs by a number of distinct
mechanisms: (i) inhibition of TGF-β, (ii) regulation of ECM synthesis and turnover and by (iii)
regulating cell death, adhesion and migration.
1The SLRP modulating the respective matricellular function is indicated as subscript and abbreviated as follows: D, decorin; B, biglycan; L,
lumican
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dulin with collagen requires more than one binding domain,
similar to class I SLRPs. One of these domains appears to be
the C-terminal end of the molecule containing the disulfide
loop (Font et al. 1998), and the binding to collagen I involves
LRR5-7 of the protein core (Kalamajski and Oldberg 2009).
Cellular proliferation
The multitude of matricellular functions performed by
SLRPs is further evidenced by their ability to regulate
cellular proliferation. Decorin has long been known to
regulate cellular growth, as ectopic overexpression of
decorin retarded cell growth (Yamaguchi and Ruoslahti
1988). Diverse mechanisms of growth regulation by
decorin have been revealed over the years and these were
attributed to its ability to, (i) engage receptors modulating
signaling pathways, (ii) act as a growth factor, and (iii)
influence regulation at certain cell cycle checkpoints. Decorin
inhibits cellular proliferation in a TGF-β-dependent manner
in Chinese hamster ovary (CHO) cells (Yamaguchi et al.
1990), arterial smooth muscle cells (Fischer et al. 2001),
human hepatic stellate cells (Shi et al. 2006), and fibroblasts
(Zhang et al. 2007). However, the majority of data
concerning decorin-mediated regulation of proliferation was
generated in carcinoma cell lines. In tumor cells, decorin
binds EGFR and ErbB4, leading to activation of the
mitogen-activated protein kinase (MAPK) pathway, Ca
2+
influx, induction of the cyclin-dependent kinase (CDK)
inhibitor p21 with subsequent downregulation of the receptor
(Csordas et al. 2000;D eL u c ae ta l .1996; Iozzo et al. 1999;
Moscatello et al. 1998;; Santra et al. 2002). Decorin-bound
EGFR is further internalized and degraded (Zhu et al. 2005).
Thus, these extensive studies provide a molecular explana-
tion for the antiproliferative and antioncogenic effects of
decorin (Reed et al. 2002; Seidler et al. 2006). Moreover,
there is a direct link between decorin deficiency and
spontaneous tumor formation (Bi et al. 2008). For further
details more extensive reviews are suggested (Goldoni and
Iozzo 2008; Nikitovic et al. 2008a). Recently, decorin has
been shown to inhibit proliferation of trophoblasts through
the EGFR and vascular endothelial growth factor receptor-2
(VEGF-R2) signaling pathways (Iacob et al. 2008), indicat-
ing that these mechanisms are not restricted to regulation of
carcinoma cell proliferation. Interestingly, by binding myo-
statin and modulating its down-stream signals, decorin can
rescue the inhibitory effects of myostatin on myoblast
proliferation, thereby acting indirectly as a promoter of cell
proliferation (Brandan et al. 2008; Miura et al. 2006).
The role of biglycan in regulating cellular proliferation
was addressed only by a limited number of studies.
Antiproliferative effects of biglycan were observed in
mesangial cells of the kidney, where it inhibited PDGF-
BB-induced proliferation (Schaefer et al. 2003) and in bone
marrow stromal cells, where WISP-1 blocked the antipro-
liferative effects of biglycan (Inkson et al. 2009). In
pancreatic cancer cells, biglycan induced G1 arrest, thereby
inhibiting tumor cell proliferation. This effect was asso-
ciated with upregulation of the CDK inhibitor p27 and
downregulation of cyclin A and proliferating cell nuclear
antigen, along with decreased activation of Ras and Erk
Fig. 1 Cell type-specific func-
tions mediated by decorin via
modulation of IGF-IR signaling.
Decorin binds and induces phos-
phorylation of the insulin-like
growth factor-I (IGF-I) receptor,
causing downstream activation of
phosphoinositide-3 kinase (PI3K)
and the Akt/protein kinase B
(Akt/PKB) pathway. In endothe-
lial and renal tubular epithelial
cells this signaling cascade leads
to an inhibition of apoptosis,
whereas in renal fibroblasts sig-
naling through mammalian target
of rapamycin (mTOR) and p70S6
Kinase (p70S6K) leads to
increased translation and synthe-
sis of fibrillin-1. These pathways
demonstrate the intricate regula-
tory mechanisms whereby
decorin modulates IGF-IR sig-
naling in a cell type-specific
manner, thereby giving rise to
different biological outcomes
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cells biglycan has been shown to favor proliferation in a
CDK2- and p27-dependent manner (Shimizu-Hirota et al.
2004). Moreover, the proliferative phase of osteoblast
development was associated with increased expression of
biglycan, indirectly indicating that biglycan might promote
proliferation (Waddington et al. 2003). Based on these data,
it is tempting to speculate that similar to decorin, biglycan
might regulate proliferation in a cell type-specific manner,
either directly via a specific receptor or by contributing to
the crosstalk between signaling pathways, or by an indirect
mechanism. To interpret these data in more detail, studies
on biglycan-mediated signaling are warranted. Up to now,
the Toll-like receptors-2 and -4 have been identified as
signaling receptors for biglycan (Schaefer et al. 2005),
whereas unlike decorin it was found not to signal through
the EGFR (Moscatello et al. 1998).
Similar to decorin, lumican also acts as a negative
regulator of cellular proliferation, by upregulating the
expression of the CDK inhibitor p21 (Li et al. 2004), but
it appears that the underlying mechanisms are different.
Lumican inhibits proliferation of mouse embryonic fibro-
blasts by upregulating p21 in a p53-dependent mechanism
with decreased cyclin A, D1 and E (Vij et al. 2004). Lack
of lumican has been shown to promote proliferation of
stromal keratinocytes and embryonic fibroblasts (Vij et al.
2005). Its inhibitory effects on growth are extended to
tumor cells, with some of these cells secreting lumican in
an autocrine manner (Sifaki et al. 2006). Lumican regulates
vertical growth and inhibits anchorage-independent prolif-
eration and cyclin D1 expression in melanoma cells
(Brezillon et al. 2007; Vuillermoz et al. 2004). Further
details concerning the role of lumican in controlling tumor
growth are included in recent reviews (Goldoni and Iozzo
2008; Naito 2005; Nikitovic et al. 2008b).
Programmed cell death
SLRPs act as modulators of programmed cell death.
Decorin prevents apoptosis in tubular epithelial cells
(Schaefer et al. 2002), endothelial cells, and bone marrow
stromal cells (Bi et al. 2005). In tubular epithelial and
endothelial cells, the anti-apoptotic effects of decorin are
mediated by binding to the IGF-IR and signaling via the
PI3K/Akt pathway, which also plays a role in fibrosis
(details are described in the section “Fibrosis” below) and
angiogenesis (Fig. 1) (Schaefer et al. 2007; Schonherr et al.
2005; Schonherr et al. 2004). It appears that signaling
through the canonical IGF pathway may represent a
common mechanism by which decorin protects non-
carcinoma cells from programmed cell death.
Conversely, in carcinoma cells decorin has been shown
to enhance apoptosis via the EGFR and enhanced caspase-3
activity, indicating an additional mechanism, which might
explain the anti-oncogenic effects of decorin (Seidler et al.
2006; Tralhao et al. 2003). The role of biglycan and
lumican in the regulation of cell survival has not been
studied in detail. Biglycan has been shown to protect
mesangial cells from apoptosis by decreasing caspase-3
activity (Schaefer et al. 2003). By contrast, lumican
mediates Fas-FasL-induced apoptosis by inducing Fas
(CD95) in mouse embryonic fibroblasts (Vij et al. 2004).
The ability of lumican to induce apoptosis has also been
reported in tumor cells and could be used to control tumor
progression (Vuillermoz et al. 2004).
Interactions with cytokines and growth factors
Decorin, biglycan, asporin, and fibromodulin bind the
profibrotic cytokine TGF-β (Hildebrand et al. 1994;
Nakajima et al. 2007). However, since TGF-β interacts
with conserved leucine-rich repeat structures (Schonherr et
al. 1998), it is likely that other SLRPs are also able to form
complexes with this cytokine. A lot of attention has been
focused on the interaction of decorin with TGF-β, as it had
been demonstrated unequivocally that decorin treatment
exerts beneficial effects in fibrotic disorders involving
TGF-β overproduction in the kidney and other organs
(Border et al. 1992; Kolb et al. 2001). Besides inhibition of
TGF-β-mediated fibrosis, the binding of decorin to TGF-β
has significant biological implications in regulating a
number of cellular processes, e. g. (i) modulation of cell
proliferation (Li et al. 2008; Yamaguchi et al. 1990), (ii)
inhibition of repressive effects of TGF-β on macrophages
leading to their activation (Comalada et al. 2003), and (iii)
suppression of TGF-β-dependent apoptosis in bone marrow
stromal cells (Bi et al. 2005). Several mechanisms for the
decorin-mediated inactivation of TGF-β have been postu-
lated, e. g. (i) interaction with TGF-β signaling, either
directly or indirectly by regulating modulators of the TGF-
β pathway (e. g. fibrillin-1, myostatin) (Abdel-Wahab et al.
2002; Brandan et al. 2008; Schaefer et al. 2007; Yamaguchi
et al. 1990; Zhu et al. 2007), (ii) formation of decorin/TGF-
β complexes, which are either eliminated from the tissue
(via the circulation or by urinary excretion) or in the presence
of collagen I are sequestered in the ECM (Schaefer et al.
2001). Conversely, the interaction of decorin with TGF-β
could also enhance the bioactivity of TGF-β,a ss e e ni nt h e
process of bone formation during remodeling (Takeuchi et
al. 1994). The mechanism of interaction of decorin with
TGF-β has been described at length in earlier reviews
(Iozzo, 1998; Kresse and Schonherr 2001).
328 R. Merline et al.Besides its interaction with the IGF-IR, decorin can also
bind IGF-I but with a 1000-fold lower affinity than the
classical IGF-I-binding proteins, indicating that decorin is
more likely to compete with IGF-I for binding to the IGF-
IR, rather than with the binding proteins which have KD
values in the range of 10
-10M. This suggests that only in
situations where decorin is expressed abundantly relevant
competition with the classical binding proteins might occur
(Schonherr et al. 2005). Decorin binds PDGF, inhibiting
downstream phosphorylation of the PDGFR and signaling
inaorticsmoothmusclecells.Theseeffectscouldbeexploited
therapeutically to prevent intimal hyperplasia (Nili et al.
2003). Through its GAG chains, decorin interacts with the
von Willebrand factor and is involved in the modulation of
ECM organization (Guidetti et al. 2004). Decorin and
biglycan also bind and immobilize the proinflammatory
cytokine TNFα (Tufvesson and Westergren-Thorsson 2002).
Both SLRPs interact with WISP-I, regulating its function in
fibroblasts and osteogenic cells (Desnoyers et al. 2001;
Inkson et al. 2009). Biglycan also modulates the activity of
BMP-4 on osteoblast differentiation (Chen et al. 2004).
Furthermore, biglycan and fibromodulin were found to
modulate bone morphogenic protein signaling, affecting
differentiation of tendon stem progenitor cells, thereby
influencing tendon formation (Bi et al. 2007).
The SLRPs have been shown to regulate embryonic
development by modulating the activity of various growth
factors. Biglycan forms complexes with BMP-4 enhancing
its binding to chordin, which leads to its inactivation by the
chordin-Tsg (Twisted gastrulation) complex (Moreno et al.
2005). Tsukushi, another member of the SLRP family, acts
as a modulator of cellular functions by regulating BMP-4,
fibroblast growth factor (FGF) and Xenopus nodal-related
protein-2 (Xnr2) signaling (Kuriyama et al. 2006; Morris et
al. 2007; Ohta et al. 2006). The binding and regulation of
asporin to growth factors and its modulatory effects have
been considered in a recent review (Ikegawa 2008). By
their ability to interact with different growth factors, the
SLRPs exhibit regulatory effects on various cellular
processes, including development.
Inflammation and innate immunity
There is growing evidence for a significant role of SLRPs
as direct and indirect endogenous modulators of inflamma-
tion and innate immunity (Al Haj Zen et al. 2006; Schaefer
et al. 2002, 2005; Vij et al. 2005). Biglycan, besides being
sequestered in the ECM, can also exist as a soluble
molecule, e.g. when it is released from the ECM by
proteolytic digestion of injured tissues or secreted by
activated macrophages (for schematic drawing please see
Schaefer and Schaefer 2009). Similar to pathogen-
associated molecular patterns (PAMPs), soluble biglycan
acts as an endogenous ligand of TLR4 and TLR2 in
macrophages. These interactions lead to activation and
downstream signaling, via p38, p42/44, and NFκBi na
MyD88-dependent manner and subsequent synthesis and
secretion of pro-inflammatory cytokines (Schaefer et al.
2005). Both the protein core and the GAG chains of
biglycan are required for activation of these pathways.
Generation of TNFα and MIP2 enhances recruitment of
macrophages and neutrophils, which in turn secrete
additional biglycan, thereby creating a positive feedback
loop that stimulates autocrine and paracrine inflammatory
responses. The clinical significance of this has been
shown by a survival benefit of biglycan-null mice in
TLR4- (gram-negative) or TLR2-dependent (gram-positive)
sepsis. Improved survival in this model was associated with
lower plasma levels of TNFα and reduced infiltration of
mononuclear cells into the lung, a major target organ of
sepsis in mice (Schaefer et al. 2005). In a model of non-
infectious inflammatory renal injury, overexpression of
biglycan in the kidney was associated with increased
numbers of infiltrating mononuclear cells (Babelova et al.
2009; Schaefer et al. 2002). What is more, soluble biglycan
activates the NLRP3/ASC inflammasome by inducing
caspase-1 and releasing mature IL-1β without further need
for additional costimulatory factors. In terms of receptors
involved, biglycan interacts with TLR2/4 and purinergic
P2X4/P2X7 receptors, thereby inducing receptor coopera-
tivity (Babelova et al. 2009). In addition, formation of
reactive oxygen species (ROS) appears also to be involved
in biglycan-mediated activation of the inflammasome
(Babelova et al. 2009). Under pathological conditions, in
a model of inflammatory renal injury (unilateral ureteral
obstruction) and in LPS-induced sepsis, biglycan deficiency
was associated with lower levels of active caspase-1 and
mature IL-1β in kidneys, lungs and in the circulation
(Babelova et al. 2009). It is tempting to speculate that
biglycan upon its release from the ECM acts as an
autonomous trigger of the inflammatory response reaction.
On the other hand, in pathogen-driven inflammation biglycan
mightpotentiatePAMP-triggeredinflammationbyengaginga
second TLR that is not involved in pathogen-sensing.
Indirectly, SLRPs may modulate the innate immune
response at various levels. SLRPs can influence TLR
signaling by presenting PAMPs to the receptor complex.
This is evident in the ability of lumican core protein to bind
and present lipopolysaccharide to CD14, thereby activating
the TLR4 pathway (Wu et al. 2007). In addition, SLRPs
enhance the activation of the immune system by their
ability to modulate the activity of TGF-β, a potent immuno-
suppressive cytokine (Wojtowicz-Praga 2003). Similar to
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by various mechanisms, especially by its effects on macro-
phages. It binds TGF-β and reverses its repressive effect on
macrophages. Furthermore, it inhibits macrophage prolifer-
ation and apoptosis and enhances the synthesis of pro-
inflammatory cytokines and inducible nitric oxide synthase
(iNOS) (Comalada et al. 2003). The anti-proliferative and
anti-apoptotic effects of decorin on macrophages are
mediated by inducing the inhibitors of the CDKs p27
(Kip1) and p21(Waf1), which are important for cell cycle
regulation. What is more, decorin also inhibits the effects of
the macrophage colony stimulating factor (Xaus et al. 2001).
The SLRPs are also involved in the recruitment of
immune cells to the site of injury, either directly by acting
as ligands to cell surface receptors or indirectly by different
mechanisms. Decorin stimulates the production of MCP-1,
a mononuclear cell-recruiting chemokine, thereby sustain-
ing the inflammatory state (Koninger et al. 2006). Biglycan,
besides its interaction with TLRs (Schaefer et al. 2005),
acts as a ligand for selectin L/CD44 and is directly involved
in the recruitment of CD16(-) natural killer cells (Kitaya
and Yasuo 2009). Lumican, by binding and signaling via
FasL, enhances the synthesis and secretion of proinflam-
matory cytokines and the recruitment of macrophages and
neutrophils (Funderburgh et al. 1997; Vij et al. 2005). The
core protein of lumican binds the CXC-chemokine KC
(CXCL1), establishing a chemokine gradient that regulates
neutrophil infiltration (Carlson et al. 2007). Furthermore,
decorin, biglycan, fibromodulin, osteoadherin and chon-
droadherin bind C1q, resulting in the case of fibromodulin,
osteoadherin, and chondroadherin in activation of the
classical complement pathway, and leading to an enhanced
inflammatory response (Sjoberg et al. 2009).
Thus, SLRPs by: (i) acting as PAMP analogues, (ii)
aiding the presentation of PAMPs to the receptor complex,
or (iii) interacting with various cytokines, chemokines and
complement factors, modulate inflammation and innate
immunity by a host of mechanisms, both in non-infectious
and in pathogen-mediated inflammatory conditions.
Fibrosis
Taking into account all matricellular functions of SLRPs
mentioned above, including the regulation of cell behavior,
the synthesis and degradation of the ECM, the activity of
profibrotic factors, and the recruitment of infiltrating cells,
SLRPs are undoubtedly important players in fibrogenesis.
While fibrosis occurs in diverse organs, its pathological
hallmarks are quite comparable, irrespective of the tissue
affected. These include: (i) enhanced and aberrant activa-
tion of profibrotic growth factors (e. g. TGF-β); (ii)
accumulation of activated (myo)fibroblasts; (iii) altered
composition and increased deposition of ECM; and (iv)
persistent inflammation, which perpetuates fibrotic trans-
formation (Hewitson 2009). Among various SLRPs, a lot of
attention has been focused on the antifibrotic effects of
decorin as a neutralizing factor of TGF-β (Border et al.
1992; Yamaguchi and Ruoslahti 1988). In several models
of fibrosis it was shown that treatment with decorin
considerably attenuated fibrogenesis, regardless of tissue
and mode of decorin administration (Al Haj Zen et al. 2006,
Border et al. 1992; Fukui et al. 2001; Grisanti et al. 2005;
Huijun et al. 2005; Isaka et al. 1996; Kolb et al. 2001;
Krishna et al. 2006). Two decades of investigations, after
the initial observation by Border et al. (1992) confirmed
the antifibrotic effects of decorin in a host of organs, such
as the kidney (Schaefer et al. 2002; Williams et al. 2007),
lung (Kolb et al. 2001), heart (Weis et al. 2005), skeletal
muscle (Brandan et al. 2008), liver (Shi et al. 2006), blood
vessels (Al Haj Zen et al. 2006), skin (Krishna et al. 2006),
and conjunctiva (Grisanti et al. 2005). Furthermore, our
understanding of the underlying mechanisms have improved
considerably. There is now good evidence that decorin
involves multiple signaling pathways by its interactions
with the IGF-IR, EGFR, LRP-1 and c-Met (Goldoni et al.
2009; Schaefer and Iozzo 2008). Thus, it appears that it is
not the direct physical interaction of decorin with TGF-β
(Hildebrand et al. 1994; Schonherr et al. 1998) but rather its
interference with the TGF-β signaling cascade (described
in the section “Interactions with cytokines and growth
factors”, above) that plays a key role in the neutralization of
this cytokine. Furthermore, the binding of decorin to TGF-
β and collagen I has been shown to be important for
sequestration of the cytokine in the ECM (Markmann et al.
2000; Schaefer et al. 2001). Interestingly, even by trigger-
ing the same pathway decorin may give rise to distinct
biological outcomes (Fig. 1), depending on the cell type
and biological context. In this light, previous observations
regarding the consequences of decorin/TGF-β interactions,
implicating inactivation (Border et al. 1992), activation
(Takeuchi et al. 1994) or lack of effects on TGF-β activity
(Hausser et al. 1994), do not appear irreconcilable any
longer.
The antifibrotic effects of decorin are not only limited to
its interaction with TGF-β but involve other mechanisms as
well (Schaefer et al. 2002). Decorin deficiency (Danielson
et al. 1997) aggravated renal fibrosis significantly in
unilateral ureteral obstruction or diabetic nephropathy due
to enhanced apoptosis of tubular epithelial cells (Schaefer et
al. 2002). Acceleration of apoptosis was independent of
TGF-β and was based on direct interaction of decorin with
the IGF-IR in tubular epithelial cells, followed by phos-
phorylation of the receptor and activation of Akt/PKB
(Fig. 1) (Merline et al. 2009; Schaefer et al. 2002; Schaefer
et al. 2007; Schonherr et al. 2005). Furthermore: (i) collagen
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even though synthesis was enhanced, suggesting that decorin
may protect collagen fibrils from proteolytic digestion (Geng
et al. 2006;S c h a e f e re ta l .2002); (ii) TGF-β activity was
enhanced, underlining the importance of decorin in TGF-β
inactivation; and (iii) proinflammatory biglycan was upregu-
lated, resulting in enhanced infiltration of mononuclear cells.
In the heart, the absence of decorin resulted in abnormal scar
formation after myocardial infarction (Weis et al. 2005).
Theabilityofdecorintoregulateadhesionandmigrationin
a cell-dependentmannerfurther underlinesitscomplexrolein
fibrogenesis. In fibroblasts deficient in decorin, increased cell
spreading was reported (Gu and Wada 1996), while exoge-
nous addition of decorin inhibited fibroblast adhesion to a
variety of substrates, indicating the anti-adhesive effects of
decorin (Gu and Wada 1996; Winnemoller et al. 1991;
Winnemoller et al. 1992). Conversely, by binding and
signaling via the IGF-IR and integrin α2β1, decorin
promotes endothelial cell adhesion and migration on
collagen type I (Fiedler et al. 2008). In fibroblasts, the core
protein of decorin induced increased synthesis and activation
of RhoA and Rac1 and has been shown to remodel lung
fibroblasts enhancing their migration by inducing morpho-
logical and cytoskeletal changes (Tufvesson and Westergren-
Thorsson 2003). Thus, decorin appears to be a potent
antifibrotic molecule, influencing fibrogenesis in different
organs by a number of distinct mechanisms, i.e. by inhibition
of TGF-β, regulation of ECM synthesis and turnover,
modulation of cell death, and adhesion and migration).
The role of biglycan in fibrogenesis is not well
understood. No beneficial effects were seen in pulmonary
fibrosis when biglycan instead of decorin was adenovirally
induced (Kolb et al. 2001). This is conceivable, taking into
account that the proinflammatory effects of biglycan are
mediated via TLR2/4 (described in the section “Inflammation
and innate immunity”). Recently, biglycan has been shown to
be protective in cardiac fibrosis following myocardial
infarction, based on its ability to regulate collagen formation
(Westermann et al. 2008). It is tempting to speculate that
SLRPs may have different functions resulting in different
biological outcomes, depending on whether these molecules
are soluble and can engage cell surface receptors or are
incorporated in the ECM and are therefore unable to act
as receptor ligands. Further investigations are warranted
to elucidate the role of biglycan in inflammation and
fibrogenesis.
Future perspectives
Taking into account the many modulatory functions
exhibited by SLRPs at the molecular and cellular levels,
i.e. controlling morphogenesis, cellular growth, apoptosis
and inflammation among other functions, makes the study
of SLRPs as matricellular proteins aptly worthwhile. Future
research should aim at translating our rapidly expanding
knowledge of these matricellular proteins into the clinical
setting by identifying promising drug targets and defining
new therapeutic strategies to treat inflammatory, fibrotic,
and malignant disorders.
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